Research programme: G-protein coupled receptor-targeting antibodies - Pfizer/Ab Initio Biotherapeutics

Drug Profile

Research programme: G-protein coupled receptor-targeting antibodies - Pfizer/Ab Initio Biotherapeutics

Latest Information Update: 03 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ab Initio Biotherapeutics
  • Developer Ab Initio Biotherapeutics; Pfizer
  • Class Antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Cardiovascular disorders; Endocrine disorders; Gastrointestinal disorders; Neurological disorders

Most Recent Events

  • 14 Dec 2016 Ab Initio Biotherapeutics enters into a license agreement with Pfizer to discover therapeutic antibodies against an undisclosed target in the G-protein coupled receptor superfamily
  • 14 Dec 2016 Early research in Cardiovascular disorders in USA (unspecified route)
  • 14 Dec 2016 Early research in Endocrine disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top